Omez (Omeprazole)

Omeprazole, the active ingredient in Omez, is a Proton Pump Inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omez (omeprazole) is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication success. - NSAID‑associated ulcer prevention: lowers risk of ulcer development in at‑risk patients.

Adverse reactions to omeprazole may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: typically self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: severe skin reactions. - Hepatotoxicity: liver enzyme elevations. - Fracture risk: potential reduction in bone mineral density with long‑term use.

When using Omez, consider the following safety measures:

- Assess renal function: dose adjustment may be needed in severe impairment. - Evaluate hepatic function: use with caution in moderate to severe liver disease. - Monitor for infections: prolonged acid suppression can increase risk of gastrointestinal infections. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral absorption, compromising HIV therapy. - Dasatinib: lowered plasma concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Methotrexate: elevated serum levels, especially with high‑dose regimens. - Digoxin: increased serum concentration, may need dose adjustment.